Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15734453.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Angiotensin-converting enzyme inhibitors have been shown to prolong survival and decrease infarct size in patients after acute coronary syndromes. Now there is evidence to suggest that angiotensin-converting enzyme inhibition is beneficial in coronary artery bypass patients. This review will summarize the beneficial effects of angiotensin-converting enzyme inhibition in patients with ischemic heart disease and provide evidence to show that the routine use of angiotensin-converting enzyme inhibition in coronary artery bypass patients can improve clinical outcomes.
Medical subject headings
- Angiotensin-Converting Enzyme Inhibitors
- Coronary Artery Bypass
- Postoperative Complications